Carvedilol improves energy production during acute global myocardial ischaemia

European Journal of Pharmacology

Volumn 482, Issue 1-3, 2003, Pages 245-253

  Monteiro, Pedro ^a   Duarte, Ana I ^b   Moreno, António ^b   Gonçalves, Lino M ^a,b   Providência, Luís A ^b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Carvedilol; Ischaemia; Mitochondrion

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRIC POTENTIAL; ENERGY YIELD; HEART MITOCHONDRION; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART PERFUSION; ISOLATED HEART; MITOCHONDRIAL MEMBRANE; NONHUMAN; OXYGEN CONSUMPTION; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN;

EID: 0344253727     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.09.042     Document Type: Article

References (44)

1. Abreu R.M., Santos D.J., Moreno A.J. Effects of carvedilol and its analog BM-910228 on mitochondrial function and oxidative stress. J. Pharmacol. Exp. Ther. 295:2000;1022-1030.
2. Cleland J.G., McGowan J. Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression. J. Cardiovasc. Pharmacol. 33(Suppl. 3):1999;S17-S29.
3. Cleland J.G., McGowan J., Clark A., Freemantle N. The evidence for beta-blockers in heart failure. BMJ. 318:1999;824-825.
4. Colucci W.S., Packer M., Bristow M.B., Gilbert E.M., Cohn J.N., Fowler M.B., Krueger S.K., Hershberger R., Uretsky B.F., Bowers J.A., Sackner-Bernstein J.D., Young S.T., Holcslaw T.L., Lukas M.A. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
5. Crestanello J.A., Doliba N.M., Babsky A.M., Doliba N.M., Niibori K., Osbakken M.D., Whitman G.J. Mitochondrial function during ischemic preconditioning. Surgery. 131:2002;172-178.
6. Crestanello J.A., Doliba N.M., Babsky A.M., Doliba N.M., Niibori K., Whitman G.J., Osbakken M.D. Ischemic preconditioning improves mitochondrial tolerance to experimental calcium overload. J. Surg. Res. 103:2002;243-251.
7. Dargie H.J. Design and methodology of the CAPRICORN trial - a randomized double-blind placebo-controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur. J. Heart Fail. 2:2000;325-332.
8. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 357:2001;1385-1390.
9. Dargie H.J., Colucci W.S., Ford I., Lopez-Sendon J.-L., Remme W.J., Sharpe N. CAPRICORN - a study of carvedilol post myocardial infarction. Cardiovasc. Drugs Ther. 13:1999;24. (Abstract).
10. Dunn C.J., Lea A.P., Wagstall A.J. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 54:1997;161-185.
11. Feuerstein G.Z., Ruffolo R.R. Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur. Heart J. 16(Suppl. F):1995;38-42.
12. Feuerstein G.Z., Yue T.L., Cheng H.Y., Ruffolo R.R. Jr. Myocardial protection by the novel vasodilating beta-blocker, carvedilol. Potential relevance of anti-oxidant activity. J. Hypertens. 11(Suppl. 1):1993;S41-S48.
13. Feuerstein G., Yue T.L., Ma X., Ruffolo R.R. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog. Cardiovasc. Dis. 41:1998;17-24.
14. Dietary supplementation with n-3 polyunsaturated fatty acids and Vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 354:1999;447-455.
15. Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of biuret reaction. J. Biol. Chem. 177:1949;751-766.
16. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;23-33.
17. Jassem W., Fuggle S.V., Rela M., Koo D.D.H., Heaton N.D. The role of mitochondria in ischemia/reperfusion injury. Transplantation. 73:2002;493-499.
18. Kamo N., Muratsugu M., Hongoh R., Kobatake Y. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenyl phosphonium and relationship between proton electrochemical potential and phosphorylation potential in steady state. J. Membr. Biol. 49:1979;105-121.
19. King T.E. Succinate cytochrome c oxidoreductase assay. Methods Enzymol. 10:1967;217.
20. Lysko P.G., Lysko K.A., Webb C.L., Feuerstein G.Z. Neuroprotective effects of carvedilol, a new antihypertensive, at the N-methyl-D-aspartate receptor. Neurosci. Lett. 148:1992;34-38.
21. Lysko P.G., Lysko K.A., Yue T.L., Webb C.L., Gu J.L., Feuerstein G.Z. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke. 23:1992;1630-1635.
22. Madeira V.M.C., Antunes-Madeira M.C., Carvalho A.P. Activation energies of the ATPase activity of sarcoplasmic reticulum. Biochem. Biophys. Res. Commun. 58:1974;897-904.
23. Muratsugu M., Kamo N., Kurihara K., Kobatabe Y. Selective electrode for dibenzyl dimethyl ammonium cation as indicator of the membrane potential in electrical systems. Biochim. Biophys. Acta. 464:1977;613-619.
24. National Research Council Guide for the Care and Use of Laboratory Animals. 1996;National Academy Press, Washington, DC.
25. Noguchi N., Nishino K., Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem. Pharmacol. 59:2000;1069-1076.
26. Oliveira P.J., Marques M.P., Batista de Carvalho L.A., Moreno A.J. Effects of carvedilol on isolated heart mitochondria: evidence for a protonophoretic mechanism. Biochem. Biophys. Res. Commun. 276:2000;82-87.
27. Oliveira P.J., Coxito P.M., Rolo A.P., Santos D.L., Palmeira C.M., Moreno A.J. Inhibitory effect of carvedilol in the high-conductance state of the mitochondrial permeability transition pore. Eur. J. Pharmacol. 412:2001;231-237.
28. Oliveira P.J., Rolo A.P., Monteiro P., Gonçalves L., Palmeira C.M., Moreno A.J. Impact of carvedilol on the mitochondrial damage induced by hypoxanthine and xantine oxidase - what role in myocardial ischemia and reperfusion? Rev. Port. Cardiol. 21:2002;1447-1455.
29. Packer M.et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334:1996;1344-1349.
30. Packer M.et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344:2001;1651-1658.
31. Rickwood D., Wilson M.T., Darley-Usmar V.M. Isolation and characteristics of intact mitochondria - isolation of mitochondria from mammalian cells. Darley-Usmar V.M., Rickwood D., Wilson M.T. Mitochondria: A Practical Approach. 1987;4-5 IRL Press, Oxford.
32. Rickwood D., Wilson M.T., Darley-Usmar V.M. Isolation and characteristics of intact mitochondria - isolation of mitochondria from mammalian cells. Darley-Usmar V.M., Rickwood D., Wilson M.T. Mitochondria: A Practical Approach. 1987;11-13 IRL Press, Oxford.
33. Rolo A.P., Oliveira P.J., Moreno A.J., Palmeira C.M. Protective effect of carvedilol on chenodeoxycholate induction of the permeability transition pore. Biochem. Pharmacol. 61:2001;1449-1454.
34. Ruffolo R.R. Jr., Bril A., Feuerstein G.Z. Cardioprotective potential of carvedilol. Cardiology. 82:1993;24-28.
35. Ryan, T.J., Antman, E.M., Brooks, N.H., Califf, R.M., Hillis, H.D., Hiratzka, L.F., Rapaport, E., Riegel, B., Russell, R.O., Smith, E.E. III, Weaver, W.D., 1999. ACC/AHA guidelines of the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Available at www.acc.org . Accessed on September 15, 2002.
36. Santos D.J., Moreno A.J. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228. Biochem. Pharmacol. 61:2001;155-164.
37. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781-786.
38. Stocchi V., Cucchiarini L., Magnani M., Chiarantini L., Palma P., Crescentini G. Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells. Anal. Biochem. 146:1985;118-124.
39. The Heart Outcomes Prevention Evaluation Study Investigators Vitamin E supplementation and cardiovascular events in high-risk patients. N. Engl. J. Med. 342:2000;154-160.
40. Yaoita H., Sakabe A., Maehara K., Maruyama Y. Different effects of carvediolol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation. 105:2002;975-980.
41. Yue T.L., Cheng H.Y., Lysko P.G., McKenna P.J., Feuerstein R., Gu J.L., Lysko K.A., Davis L.L., Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. 263:1992;92-98.
42. Yue T.L., McKenna P.J., Gu J.L., Cheng H.Y., Ruffolo R.R. Jr., Feuerstein G.Z. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension. 22:1993;922-928.
43. Yue T.L., Lysko P.G., Brone F.C., Gu J.L., Ruffolo R.R. Jr., Feuerstein G.Z. Carvedilol, a new antihypertensive drug with unique antioxidant activity: potential role in cerebroprotection. Ann. N.Y. Acad. Sci. 738:1994;230-242.
44. Yue T.L., McKenna P.J., Gu J.L., Cheng H.Y., Ruffolo R.R. Jr., Feuerstein G.Z. Carvedilol, a new vasodilating β-adrenoceptor blocker antyhipertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc. Res. 28:1994;400-406.